{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:31:03Z","timestamp":1794360663276,"version":"4.9.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Holding SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.euo.2024.10.012","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T07:03:29Z","timestamp":1731654209000},"page":"216-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Unmet Need in Non\u2013muscle-invasive Bladder Cancer Failing Bacillus Calmette-Gu\u00e9rin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group"],"prefix":"10.1016","volume":"8","author":[{"given":"David","family":"D\u2019Andrea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Mostafid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.10.012_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0010","doi-asserted-by":"crossref","unstructured":"Subiela JD, Krajewski W, Gonz\u00e1lez-Padilla DA, et al. Unlocking the potential of adequate bacillus Calmette-Gu\u00e9rin immunotherapy in very-high-risk non-muscle-invasive bladder carcinoma: a multicenter analysis of oncological outcomes and risk dynamics. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2024.01.017.","DOI":"10.1016\/j.euo.2024.01.017"},{"key":"10.1016\/j.euo.2024.10.012_b0015","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0020","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.6004\/jnccn.2018.0072","article-title":"NCCN guidelines insights: bladder cancer, version 5.2018","volume":"16","author":"Flaig","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2024.10.012_b0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0030","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0035","doi-asserted-by":"crossref","unstructured":"Ajith A, Xia M, Chevalier A, Goyal T, Chen D, Gao T. LitSearch: a retrieval benchmark for scientific literature search 2024. arXiv:2407.18940.","DOI":"10.18653\/v1\/2024.emnlp-main.840"},{"key":"10.1016\/j.euo.2024.10.012_b0040","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.euo.2024.10.012_b0050","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0055","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.euo.2024.10.012_b0060","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0090-4295(97)00510-4","article-title":"Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Gu\u00e9rin","volume":"51","author":"Sarosdy","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.euo.2024.10.012_b0065","first-page":"761","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"The Valrubicin Study Group. J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0070","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette-Gu\u00e9rin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0075","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille Calmette-Gu\u00e9rin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0080","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","article-title":"Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy","volume":"24","author":"McKiernan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0085","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.urolonc.2008.05.004","article-title":"Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the eastern cooperative oncology group","volume":"27","author":"Ignatoff","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0090","first-page":"313","article-title":"A phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG refractory and BCG-intolerant patients","volume":"4","author":"Kowalski","year":"2010","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.euo.2024.10.012_b0095","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.juro.2011.03.129","article-title":"A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Gu\u00e9rin refractory nonmuscle invasive bladder cancer","volume":"186","author":"McKiernan","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0100","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0105","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.juro.2012.07.020","article-title":"A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Gu\u00e9rin","volume":"188","author":"Kowalski","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0110","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Gu\u00e9rin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0115","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Gu\u00e9rin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0120","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/02656736.2014.882021","article-title":"A pilot clinical trial of intravesical mitomycin-c and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer","volume":"30","author":"Inman","year":"2014","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.euo.2024.10.012_b0125","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.juro.2014.06.084","article-title":"Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Gu\u00e9rin treatment failure","volume":"192","author":"McKiernan","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0130","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","article-title":"Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Gu\u00e9rin","volume":"193","author":"Morales","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0135","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1245\/s10434-016-5300-6","article-title":"Phase 1b trial to evaluate tissue response to a second dose of intravesical recombinant adenoviral interferon \u03b12b formulated in Syn3 for failures of bacillus Calmette-Guerin (BCG) therapy in nonmuscle invasive bladder cancer","volume":"23","author":"Navai","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0140","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3233\/BLC-170095","article-title":"Single arm phase i\/II study of everolimus and intravesical gemcitabine in patients with primary or secondary carcinoma in situ of the bladder who failed bacillus Calmette Guerin (NCT01259063)","volume":"3","author":"Dalbagni","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euo.2024.10.012_b0145","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-16-2267","article-title":"A phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: Hoosier cancer research network trial HCRN 12\u2013157","volume":"23","author":"Hahn","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2024.10.012_b0150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-160084","article-title":"Efficacy of Mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients","volume":"3","author":"Li","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euo.2024.10.012_b0155","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.urology.2017.01.018","article-title":"Long-term survival outcomes with intravesical nanoparticle albumin-bound paclitaxel for recurrent non-muscle-invasive bladder cancer after previous bacillus Calmette-Gu\u00e9rin therapy","volume":"103","author":"Robins","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.euo.2024.10.012_b0160","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFN\u03b1\/Syn3 for patients with high-grade, bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0165","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0170","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of mitomycin c as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2024.10.012_b0175","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0180","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/JU.0000000000000919","article-title":"A phase i trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of nonmuscle invasive bacillus Calmette-Gu\u00e9rin unresponsive or recurrent\/relapsing urothelial carcinoma of the bladder","volume":"204","author":"DeCastro","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0185","first-page":"126","article-title":"Intravesical gemcitabine as bladder-preserving treatment for BCG unresponsive non-muscle-invasive bladder cancer. Results from a single-arm, open-label study. BJUI","volume":"1","author":"Hurle","year":"2020","journal-title":"Compass"},{"key":"10.1016\/j.euo.2024.10.012_b0190","doi-asserted-by":"crossref","first-page":"1748981","DOI":"10.1080\/2162402X.2020.1748981","volume":"9","author":"Rentsch","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.euo.2024.10.012_b0195","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1007\/s00345-021-03716-3","article-title":"Phase I trial of intravesical bacillus Calmette-Gu\u00e9rin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous bacillus Calmette-Gu\u00e9rin treatment","volume":"39","author":"Alanee","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0200","doi-asserted-by":"crossref","first-page":"195.e7","DOI":"10.1016\/j.urolonc.2020.09.017","article-title":"Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure","volume":"39","author":"Hurle","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0205","doi-asserted-by":"crossref","first-page":"11.e9","DOI":"10.1016\/j.urolonc.2021.07.007","article-title":"Oncofid-p-b: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: results of a prospective European multicentre study at 15 months from treatment start","volume":"40","author":"Hurle","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0210","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.euo.2023.01.013","article-title":"A phase 1b\/2 study of atezolizumab with or without bacille Calmette-Gu\u00e9rin in patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"Inman","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0215","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.euros.2022.04.015","article-title":"A phase 1b clinical study of intravesical photodynamic therapy in patients with bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer","volume":"41","author":"Kulkarni","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2024.10.012_b0220","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.eururo.2022.08.004","article-title":"First-in-human intravesical delivery of pembrolizumab identifies immune activation in bladder cancer unresponsive to bacillus Calmette-Gu\u00e9rin","volume":"82","author":"Meghani","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0225","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of atezolizumab in bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605","volume":"84","author":"Black","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0230","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","article-title":"A phase 1 trial of durvalumab in combination with bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: the Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER study","volume":"83","author":"Hahn","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0235","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1158\/1078-0432.CCR-23-0354","article-title":"A phase II study of durvalumab for bacillus Calmette-Guerin (BCG) unresponsive urothelial carcinoma in situ of the bladder","volume":"29","author":"Li","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2024.10.012_b0240","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0245","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","article-title":"Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer","volume":"35","author":"Catto","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0250","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Gu\u00e9rin after initial bacille Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2024.10.012_b0255","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000090870","article-title":"Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study","volume":"76","author":"Gacci","year":"2006","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2024.10.012_b0260","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/sj.bjc.6604074","article-title":"Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study","volume":"97","author":"Gunelli","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2024.10.012_b0265","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.juro.2013.04.077","article-title":"Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Gu\u00e9rin immunotherapy","volume":"190","author":"Lee","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0270","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.urolonc.2007.10.016","article-title":"Intravesical gemcitabine in management of BCG refractory superficial TCC of urinary bladder\u2014our experience","volume":"26","author":"Mohanty","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0275","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5582\/irdr.2022.01057","article-title":"Intravesical MgSO4 for the treatment of BCG refractory T1 G3 bladder cancer: preliminary results on efficacy and safety","volume":"11","author":"Moussa","year":"2022","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.euo.2024.10.012_b0280","first-page":"101","article-title":"Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer?","volume":"21","author":"Perdon\u00e0","year":"2010","journal-title":"A single-arm prospective trial. Anticancer Drugs"},{"key":"10.1016\/j.euo.2024.10.012_b0285","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00345-015-1595-3","article-title":"Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study","volume":"34","author":"Soria","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0290","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s10637-018-00716-w","article-title":"Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer","volume":"37","author":"Zahoor","year":"2019","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.euo.2024.10.012_b0295","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000089164","article-title":"Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Gu\u00e9rin therapy","volume":"75","author":"Bassi","year":"2005","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2024.10.012_b0300","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.juro.2010.09.073","article-title":"Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Gu\u00e9rin refractory carcinoma in situ of the bladder: results of a phase i study","volume":"185","author":"Bassi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0305","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0022-5347(01)63021-0","article-title":"Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder","volume":"160","author":"Nseyo","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0310","doi-asserted-by":"crossref","first-page":"239.e1","DOI":"10.1016\/j.urolonc.2018.01.018","article-title":"Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: a clinical decision-making tool","volume":"36","author":"D\u2019Andrea","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.10.012_b0315","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrurol.2017.125","article-title":"Characteristics and clinical significance of histological variants of bladder cancer","volume":"14","author":"Moschini","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0320","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","article-title":"Phase I trial of intravesical recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for bacillus Calmette-Gu\u00e9rin failures in nonmuscle invasive bladder cancer","volume":"190","author":"Dinney","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0325","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/JU.0000000000001515","article-title":"Cost-effectiveness analysis of pembrolizumab for bacillus Calmette-Gu\u00e9rin-unresponsive carcinoma in situ of the bladder","volume":"205","author":"Wymer","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0330","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.10.012_b0335","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.10.012_b0340","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with bacillus Calmette-Gu\u00e9rin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.10.012_b0345","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1002\/cncr.24634","article-title":"Cost-effectiveness analysis of immediate radical cystectomy versus intravesical bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer","volume":"115","author":"Kulkarni","year":"2009","journal-title":"Cancer"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T16:43:07Z","timestamp":1739205787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124002426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2588931124002426"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.10.012","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet Need in Non\u2013muscle-invasive Bladder Cancer Failing Bacillus Calmette-Gu\u00e9rin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}